爵士制药（Jazz Pharmaceuticals）今日盘中股价大涨5.01%，截至发稿时报111.24美元/股。此次股价上涨主要源于一则重大利好消息。
据悉，美国食品药品监督管理局（FDA）已批准爵士制药的新药Modeyso™（通用名：dordaviprone）用于治疗弥漫性中线胶质瘤（DMG）。这是一种罕见且侵袭性的脑肿瘤，主要影响儿童和青年人。值得注意的是，这是FDA首次批准针对具有特定突变且在既往治疗后出现进展的DMG的系统性疗法，适用于1岁及以上的儿童和成人患者。
这一突破性进展不仅为受这种毁灭性疾病影响的患者和家庭带来了新的希望，也为爵士制药开辟了新的市场。公司计划于2025年8月27日举办投资者网络会议，进一步讨论这一重要批准。市场分析人士普遍认为，这款新药的获批将为爵士制药带来可观的收益，并巩固其在罕见病治疗领域的领先地位。该消息推动了投资者的信心，促使股价出现显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.